Repository logo
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Српски
  • Yкраї́нська
  • Log In
    New user? Click here to register. Have you forgotten your password?
Repository logo
  • Colleges, Institutes & Collections
  • Browse AAU-ETD
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Српски
  • Yкраї́нська
  • Log In
    New user? Click here to register. Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Assamin Assafaw"

Now showing 1 - 2 of 2
Results Per Page
Sort Options
  • No Thumbnail Available
    Item
    Depression and Associated Factors among Adult Diabetic Patients Attending at Diabetic Follow Up Clinic of Mikilililand Health Center, Addis Ababa, Ethiopia
    (Addis Ababa University, 2023-11) Assamin Assafaw; Assefa Berihun
    Objective: The aim of this study was to assess depression and its associated factors among type-2 diabetic patients attending at diabetic follow up clinic of Mikililand health center, Addis Ababa, Ethiopia, Methods: A facility based cross-sectional study design was conducted among 159 type-2 diabetic patients attending at diabetic follow up clinic of Mikililand health center, Addis Ababa, Ethiopia, 2023. Result: The overall prevalence of depression in the study was 41.5%. Those patient living in rent house [AOR= 5.927 (95% CI = 1.743,20.148)], those with duration of diabetes >5 yrs since diagnosis [AOR = 16.038 (95% CI = 1.611,159.3648)], those having family history of diabetes [AOR = 4.419 (95% CI =1.044,18.701)], those who had or experienced diabetes related complications [AOR= 9.166 (95% CI = 2.866, 29.314)] and alcohol use status [AOR = 30.1
  • No Thumbnail Available
    Item
    Time To Antipsychotic Discontinuation After Remission Among Patients With Major Depressive Disorder With Psychotic Features At Tikur Anbessa Specialized Hospital: A Cross-Sectional Study.
    (Addis Ababa Uinverstiy, 2026) Assamin Assafaw; Dr. Getahun Belay; Professor Solomon Teferra
    Background: Major depressive disorder with psychotic features is a severe and disabling condition that requires both antidepressant and antipsychotic treatment. Most international guidelines recommend maintaining antipsychotics for 4-6 months after clinical remission, but data on actual duration and discontinuation practices in our setting is limited for major depressive disorder with psychotic feature treatment. Objective: The objective of this study is to determine the time to antipsychotic discontinuation after remission among patients with major depressive disorder with psychotic features at Tikur Anbessa Specialized Hospital, 2025. Methods: A retrospective cross-sectional study was conducted among cases with major depressive disorder at TASH who had a follow-up for the past 5 years. Census method was used to select eligible patient records from the psychiatry follow-up EMR registry. Data on demographics, clinical profiles, antipsychotic treatment duration, remission, and discontinuation status was collected. Descriptive statistics was used to summarize the data and chi-square test to measure the association between categorical variables and results were presented using tables, graphs and charts. Result: A total of 234 MDD patients were included in the study with a mean (±SD) age of 39.6 ± 14.6 years, of whom 60 (25.6%) had MDD with psychotic features, and 62 (60 MDD-PF + 2 MDD as augmentation) patients initiated antipsychotic treatment, with risperidone, 58.3% and olanzapine, 25% being the most commonly prescribed. Clinical remission was achieved in 56.4% patients receiving antipsychotics. Prolonged antipsychotic treatment was found in 65.7% patient, and 48.6% patients still continued antipsychotic treatment following remission for a mean duration of 16.2 months (median: 15.5 months, IQR:9.4 months). Comorbid medical illness was the only factor significantly associated with remission (p = 0.011). Conclusion: The findings provide evidence on rational antipsychotics use and treatment practices for patients with major depressive disorder with psychotic features who start treatment at tertiary care setting. It supports the need to develop an institutionalized or national treatment protocol; help to improve psychiatric care while Vreducing the unnecessary prolonged antipsychotics use to ease the burden on both patients and the healthcare system

Home |Privacy policy |End User Agreement |Send Feedback |Library Website

Addis Ababa University © 2023